Intravitreal C3 inhibitor (next-gen)

About Apellis Pharmaceuticals

Apellis Pharmaceuticals is a commercial-stage biopharma company focused on developing first-in-class therapies by targeting C3, the central protein of the complement system. The company has successfully brought two medicines to market—SYFOVRE® (pegcetacoplan) for geographic atrophy and EMPAVELI® (pegcetacoplan) for PNH—addressing significant unmet needs in ophthalmology and hematology. With a deep pipeline exploring C3 inhibition across rare, retinal, and neurological diseases, Apellis leverages over two decades of complement expertise to pursue life-changing treatments. The company operates with a culture of courageous science and compassion, driven by its founding scientific team.

Therapeutic Areas